Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody

Preventing autoantibody secretion by rendering self-reactive B cells functionally silent through clonal anergy has long posed the question of why fill the circulating B cell repertoire with cells that cannot secrete antibody? Here we address this question from the perspective of B cells that comprise 5 to 10% of the human circulating repertoire, expressing self-reactive surface immunoglobulins employing the IGHV4-34 heavy chain variable element. Using gene targeting to construct mice expressing a representative human IGHV4-34 antibody on the surface of many B cells, we show these cells are prevented from autoantibody secretion by B cell clonal anergy marked by downregulation of surface IgM, induction of tolerance-response mRNAs, and exclusion from the marginal zone and B1 cell subsets. This functionally tolerant state is overridden when the IGHV4-34 B cells cross-react with a virus, which stimulates the self-reactive B cells to hypermutate in germinal centers. Within 16 d of infection, 99% of daughter cells have acquired one of five heavy chain mutations that diminish binding to self but preserve virus binding, and 33% had combined 2 or 3 of these mutations to make their antibodies genetically self-tolerant and virus specific. These results demonstrate, from the perspective of a pathologically important human autoantibody class and the world's most successful virus vaccine, how human antibody specificity is sculpted in the progeny of anergic B cells to yield antibodies that bind a virus but not self.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2025-12-18
DOI
https://doi.org/10.1073/pnas.2522257122
Citations
1
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody

Megan Faulks, Joanne H. Reed, Christopher J. Jara, Stewart A. Smith et al.
1 citations
Proceedings of the National Academy of Sciences
T-cell and B-cell Immunology
0.80
article

Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody

Megan Faulks, Joanne H. Reed, Christopher J. Jara, Stewart A. Smith, David C. Tscharke, Timothy J. Peters, Deborah Lilly Burnett, Eric Chen Quin Lam, Robert Brink, Katherine Jackson, Christopher C. Goodnow, Lisa A. Miosge, Etienne Masle‐Farquhar, Amanda Russell, Sherin Zachariah
article en
1 citations

Abstract

Preventing autoantibody secretion by rendering self-reactive B cells functionally silent through clonal anergy has long posed the question of why fill the circulating B cell repertoire with cells that cannot secrete antibody? Here we address this question from the perspective of B cells that comprise 5 to 10% of the human circulating repertoire, expressing self-reactive surface immunoglobulins employing the IGHV4-34 heavy chain variable element. Using gene targeting to construct mice expressing a representative human IGHV4-34 antibody on the surface of many B cells, we show these cells are prevented from autoantibody secretion by B cell clonal anergy marked by downregulation of surface IgM, induction of tolerance-response mRNAs, and exclusion from the marginal zone and B1 cell subsets. This functionally tolerant state is overridden when the IGHV4-34 B cells cross-react with a virus, which stimulates the self-reactive B cells to hypermutate in germinal centers. Within 16 d of infection, 99% of daughter cells have acquired one of five heavy chain mutations that diminish binding to self but preserve virus binding, and 33% had combined 2 or 3 of these mutations to make their antibodies genetically self-tolerant and virus specific. These results demonstrate, from the perspective of a pathologically important human autoantibody class and the world's most successful virus vaccine, how human antibody specificity is sculpted in the progeny of anergic B cells to yield antibodies that bind a virus but not self.

Proceedings of the National Academy of SciencesVol. 122(51)
Australian National University (AU), The University of Sydney (AU), Garvan Institute of Medical Research (AU), UNSW Sydney (AU), Futures Group (United States) (US), St Vincent's Clinic (AU), Westmead Institute for Medical Research (AU)
Rebecca L. Cooper Medical Research Foundation, University of New South Wales, Medical Research Council, National Health and Medical Research Council
Openalex Percentile: Top 20%
T-cell and B-cell Immunology
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.